Tymlos injection is an injectable drug recently approved by the U.S. Food and Drug Administration (FDA) to treat adults with postmenopausal osteoporosis. Tymlos is a first-in-class synthetic peptide analogue of the naturally occurring hormone parathyroid hormone-related protein (PTHrP) and is designed to mimic the effects of naturally occurring PTHrP, a hormone involved in bone remodeling.
Tymlos is a once-daily injection designed to stimulate new bone formation in adults with severe osteoporosis, helping to reduce their risk of fractures. The drug works by activating osteoblasts, the cells that form new bone, and inhibiting osteoclasts, the cells that break down old bone. By increasing bone formation and slowing down bone breakdown, Tymlos helps strengthen bone and reduce the risk of fractures.
In clinical trials, Tymlos was found to reduce the risk of vertebral fractures by up to 73% in postmenopausal women with severe osteoporosis. In addition, the drug was found to reduce the risk of non-vertebral fractures by up to 59%. Tymlos also increases bone mineral density (BMD) in the spine, hip, and total body, further protecting against fractures.
Tymlos is an important new treatment option for people with severe osteoporosis at high risk for fractures. By increasing bone formation and reducing the risk of fractures, Tymlos can help to improve quality of life and prevent long-term disability.
The most common side effects are swelling, redness and itching at the injection site. Other side effects may include nausea, diarrhea, muscle cramps and dizziness.
You can buy tymlos for osteoporosis at softcarepharmacy.com.